CD24+CD44+CD54+EpCAM+ gastric cancer stem cells predict tumor progression and metastasis: clinical and experimental evidence.
Angel A Gómez-GallegosLizbeth Ramírez-VidalJared Becerril-RicoElizabeth Pérez-IslasZuly J Hernandez-PeraltaMariel E Toledo-GuzmánAlejandro García-CarrancáElizabeth LangleyAngélica Hernández-GuerreroFernando López-CasillasRoberto Herrera-GoepfertLuis F Oñate-OcañaElizabeth Ortiz-SánchezPublished in: Stem cell research & therapy (2023)
The CD24+CD44+CD54+EpCAM+ cells present in tissue samples from patients are true GCSCs. This extended phenotype results in better and more specific characterization of these highly tumorigenic cells. The relative quantification of CD24+CD44+CD54+EpCAM+ cells has potential clinical value, as these cells are associated with metastatic disease, making their presence an additional prognostic marker and possibly a target for the design of new antineoplastic treatments in the era of precision oncology. Overall, the extended CD24+CD44+CD54+EpCAM+ phenotype of GCSCs could support their isolation for the study of their stemness mechanisms, leading to the identification of better molecular targets for the development of both new therapeutic approaches such as oncoimmunotherapy and new diagnostic and clinical prognostic strategies for GC.
Keyphrases
- induced apoptosis
- cell cycle arrest
- circulating tumor cells
- stem cells
- end stage renal disease
- squamous cell carcinoma
- small cell lung cancer
- cell adhesion
- chronic kidney disease
- endoplasmic reticulum stress
- palliative care
- oxidative stress
- epithelial mesenchymal transition
- newly diagnosed
- long non coding rna
- human health